Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.


Journal

Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696

Informations de publication

Date de publication:
09 Dec 2020
Historique:
received: 13 08 2020
accepted: 30 11 2020
entrez: 10 12 2020
pubmed: 11 12 2020
medline: 14 9 2021
Statut: epublish

Résumé

Emerging data support a role for lipids in non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) in humans. With experimental models such data can be challenged or validated. Mice fed a low-methionine, choline-deficient (LMCD) diet develop NASH and, when injected with diethylnitrosamine (DEN), HCC. Here, lipidomic analysis was used to elucidate whether the NASH and HCC associated lipid derangements resemble the lipid profile of the human disease. Lipids were measured in the liver of mice fed a control or a LMCD diet for 16 weeks. DEN was injected at young age to initiate hepatocarcinogenesis. DEN treatment associated changes of the lipid composition and the tumor lipidome were evaluated. LMCD diet fed mice accumulated ceramides and triacylglycerols in the liver. Phospholipids enriched with monounsaturated fatty acids were also increased, whereas hepatic cholesterol levels remained unchanged in the LMCD model. Phosphatidylcholine and lysophosphatidylcholine concentrations declined in the liver of LMCD diet fed mice. The changes of most lipids associated with LMCD diet feeding were similar between water and DEN injected mice. Several polyunsaturated (PU) diacylglycerol species were already low in the liver of DEN injected mice fed the control diet. Tumors developed in the liver of LMCD diet fed mice injected with DEN. The tumor specific lipid profile, however, did not resemble the decrease of ceramides and PU phospholipids, which was consistently described in human HCC. Triacylglycerols declined in the cancer tissues, which is in accordance with a low expression of lipogenic enzymes in the tumors. The LMCD model is suitable to study NASH associated lipid reprogramming. Hepatic lipid profile was modestly modified in the DEN injected mice suggesting a function of these derangements in carcinogenesis. Lipid composition of liver tumors did not resemble the human HCC lipidome, and most notably, lipogenesis and triacylglycerol levels were suppressed.

Sections du résumé

BACKGROUND BACKGROUND
Emerging data support a role for lipids in non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) in humans. With experimental models such data can be challenged or validated. Mice fed a low-methionine, choline-deficient (LMCD) diet develop NASH and, when injected with diethylnitrosamine (DEN), HCC. Here, lipidomic analysis was used to elucidate whether the NASH and HCC associated lipid derangements resemble the lipid profile of the human disease.
METHODS METHODS
Lipids were measured in the liver of mice fed a control or a LMCD diet for 16 weeks. DEN was injected at young age to initiate hepatocarcinogenesis. DEN treatment associated changes of the lipid composition and the tumor lipidome were evaluated.
RESULTS RESULTS
LMCD diet fed mice accumulated ceramides and triacylglycerols in the liver. Phospholipids enriched with monounsaturated fatty acids were also increased, whereas hepatic cholesterol levels remained unchanged in the LMCD model. Phosphatidylcholine and lysophosphatidylcholine concentrations declined in the liver of LMCD diet fed mice. The changes of most lipids associated with LMCD diet feeding were similar between water and DEN injected mice. Several polyunsaturated (PU) diacylglycerol species were already low in the liver of DEN injected mice fed the control diet. Tumors developed in the liver of LMCD diet fed mice injected with DEN. The tumor specific lipid profile, however, did not resemble the decrease of ceramides and PU phospholipids, which was consistently described in human HCC. Triacylglycerols declined in the cancer tissues, which is in accordance with a low expression of lipogenic enzymes in the tumors.
CONCLUSIONS CONCLUSIONS
The LMCD model is suitable to study NASH associated lipid reprogramming. Hepatic lipid profile was modestly modified in the DEN injected mice suggesting a function of these derangements in carcinogenesis. Lipid composition of liver tumors did not resemble the human HCC lipidome, and most notably, lipogenesis and triacylglycerol levels were suppressed.

Identifiants

pubmed: 33298075
doi: 10.1186/s12944-020-01425-1
pii: 10.1186/s12944-020-01425-1
pmc: PMC7727224
doi:

Substances chimiques

Ceramides 0
Lipids 0
Lysophosphatidylcholines 0
alpha-Fetoproteins 0
Diethylnitrosamine 3IQ78TTX1A
Methionine AE28F7PNPL
Choline N91BDP6H0X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

250

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : BU1141/13-1

Références

Hepatology. 2012 Jul;56(1):118-29
pubmed: 22290395
Anticancer Res. 2018 May;38(5):2649-2657
pubmed: 29715085
J Lipid Res. 2008 May;49(5):1137-46
pubmed: 18281723
Biochim Biophys Acta. 2011 Dec;1811(12):1177-85
pubmed: 21745592
Cells. 2019 May 27;8(5):
pubmed: 31137921
Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):6103-6113
pubmed: 32123069
Int J Mol Sci. 2017 Nov 28;18(12):
pubmed: 29182572
Crit Rev Biochem Mol Biol. 2018 Apr;53(2):208-230
pubmed: 29513138
Int J Mol Sci. 2014 Feb 20;15(2):2991-3002
pubmed: 24562328
Am J Physiol Gastrointest Liver Physiol. 2016 May 1;310(9):G726-38
pubmed: 26968211
Can J Biochem Physiol. 1959 Aug;37(8):911-7
pubmed: 13671378
J Lipid Res. 1999 Aug;40(8):1539-46
pubmed: 10428992
Nature. 2019 Feb;566(7744):403-406
pubmed: 30728499
J Lipid Res. 2013 Jun;54(6):1523-30
pubmed: 23549332
Exp Mol Pathol. 2014 Aug;97(1):37-43
pubmed: 24830603
Hepatology. 2007 Oct;46(4):1081-90
pubmed: 17654743
J Biol Chem. 2010 Jun 11;285(24):18528-36
pubmed: 20395294
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Mar;1864(3):344-357
pubmed: 30578966
Gastroenterology. 2018 Aug;155(2):282-302.e8
pubmed: 29906416
Cell Metab. 2006 May;3(5):321-31
pubmed: 16679290
World J Gastroenterol. 2011 Jun 21;17(23):2801-11
pubmed: 21734787
Clin Chem. 2002 Dec;48(12):2217-24
pubmed: 12446479
Trends Endocrinol Metab. 2016 Feb;27(2):84-95
pubmed: 26703097
Carcinogenesis. 1991 Jun;12(6):991-5
pubmed: 1675161
Clin Exp Gastroenterol. 2014 Jul 05;7:221-39
pubmed: 25045276
Biochem J. 1995 Dec 15;312 ( Pt 3):939-45
pubmed: 8554542
Hepatology. 2010 Aug;52(2):774-88
pubmed: 20683968
PLoS One. 2009 Nov 20;4(11):e7929
pubmed: 19936233
Cell Rep. 2018 Sep 4;24(10):2596-2605.e5
pubmed: 30184495
PLoS One. 2015 May 20;10(5):e0126910
pubmed: 25993337
Biochim Biophys Acta. 2006 Jan;1761(1):121-8
pubmed: 16458590
J Proteome Res. 2012 Nov 2;11(11):5433-42
pubmed: 22946841
Int J Biol Markers. 2004 Apr-Jun;19(2):155-9
pubmed: 15255549
J Biol Chem. 2004 Jun 4;279(23):23916-24
pubmed: 15024002
J Lipid Res. 2006 Oct;47(10):2297-305
pubmed: 16877777
Anal Chem. 2020 Aug 18;92(16):10966-10970
pubmed: 32672443
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 May;1865(5):158658
pubmed: 32058031
Biochim Biophys Acta. 2016 Nov;1861(11):1767-1774
pubmed: 27570113
Adv Exp Med Biol. 2010;688:1-23
pubmed: 20919643
Biochem Soc Trans. 2014 Oct;42(5):1447-52
pubmed: 25233430
PLoS One. 2011;6(8):e22775
pubmed: 21857953
Oxid Med Cell Longev. 2018 Nov 4;2018:7512159
pubmed: 30524660
Hepatol Commun. 2018 Jul 12;2(8):941-955
pubmed: 30094405
PLoS One. 2013 Nov 07;8(11):e79736
pubmed: 24244551
Dig Dis. 2010;28(1):247-54
pubmed: 20460919
Biochim Biophys Acta. 2016 Nov;1861(11):1828-1839
pubmed: 27591968
Anal Chem. 2019 Mar 5;91(5):3459-3466
pubmed: 30707563
Biochem Soc Trans. 2002 Nov;30(Pt 6):1091-5
pubmed: 12440980
Diabetes Care. 2018 Jun;41(6):1235-1243
pubmed: 29602794
J Am Soc Mass Spectrom. 2004 Oct;15(10):1499-508
pubmed: 15465363
J Hepatol. 2016 May;64(5):1167-1175
pubmed: 26780287
Int J Exp Pathol. 2013 Apr;94(2):93-103
pubmed: 23305254
J Hepatol. 2011 Dec;55(6):1400-8
pubmed: 21703185
Cancer Res. 2011 Nov 1;71(21):6590-600
pubmed: 21900402
Lipids Health Dis. 2019 Sep 14;18(1):172
pubmed: 31521175
World J Hepatol. 2013 Oct 27;5(10):558-67
pubmed: 24179615
Nat Commun. 2017 Mar 14;8:14689
pubmed: 28290443
Mol Oncol. 2013 Apr;7(2):206-23
pubmed: 23428636
Biochim Biophys Acta. 2004 Nov 8;1686(1-2):108-17
pubmed: 15522827
BMC Gastroenterol. 2014 Nov 20;14:195
pubmed: 25410681
Oxid Med Cell Longev. 2014;2014:360438
pubmed: 24999379
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 May;1863(5):526-537
pubmed: 29474931
Eur J Intern Med. 2017 Apr;39:32-35
pubmed: 27916437
Cell Cycle. 2017 Mar 19;16(6):499-507
pubmed: 28118080
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Clin Pract Gastroenterol Hepatol. 2005 Jun;2(6):273-80
pubmed: 16265231
Appl Physiol Nutr Metab. 2013 Mar;38(3):334-40
pubmed: 23537027
Sci Rep. 2017 Apr 24;7:46658
pubmed: 28436449

Auteurs

Elisabeth M Haberl (EM)

Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany.

Rebekka Pohl (R)

Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany.

Lisa Rein-Fischboeck (L)

Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany.

Marcus Höring (M)

Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Regensburg, Germany.

Sabrina Krautbauer (S)

Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Regensburg, Germany.

Gerhard Liebisch (G)

Institute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Regensburg, Germany.

Christa Buechler (C)

Department of Internal Medicine I, Regensburg University Hospital, Regensburg, Germany. christa.buechler@klinik.uni-regensburg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH